ArticleAbdominal radiology (New York)2026
The role of
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesHepatoid adenocarcinoma (HAC) is a rare malignant neoplasm arising in extrahepatic tissues and organs, and its prompt and correct diagnosis remains clinically challenging.
methodsA total of 66 patients with pathologically confirmed HAC underwent 71
resultsAmong 44 patients with initial HAC, the stomach was the most common primary tumor site (26/44, 59.1%). All primary tumors, with the exception of those of ovarian origin, exhibited increased FDG uptake, with a median SUVmax of 9.25. Elevated serum alpha-fetoprotein (AFP) levels were observed in 79.5% (35/44) of patients at initial diagnosis. A majority of patients (24/44, 54.5%) presented with distant metastases at the time of initial diagnosis, where the liver was the most common metastatic site (16/44, 36.4%), followed by distant lymph nodes (8/44, 18.2%) and bone (5/44, 11.4%). Notably, 50.0% (2/4) of T1-stage tumors had already developed distant metastases. The findings of
conclusion
Indexed as
Identifiers
42371017What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.